According to international medical announcements, net profit loss attributable to shareholders of listed companies is estimated to be 66 million yuan to 63 million yuan for the first half year of 2026, with a loss of 165 million yuan for the same period last year; net profit loss after deducting non-recurring profit and loss of 64.5 million yuan to 61.5 million yuan, loss of 189 million yuan for the same period of the previous year; estimated operating income of 2,028 billion yuan to 2,033 billion yuan per share, compared with a basic loss of 0.0295 yuan/share per share and a loss of 0.0730 yuan/share for the same period last year. The loss in performance was mainly due to the company's active adjustment of the business structure and implementation of measures such as cost reduction and efficiency during the reporting period, and the loss margin narrowed, but the total scale of operating income was not yet able to cover operating costs and period expenses.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.